Artis BioSolutions, a San Diego-based advanced-therapies development and manufacturing company, has agreed to acquire Syngoi Technologies, a Spanish biotechnology company pioneering novel enzymatic approaches for manufacturing synthetic DNA technologies. The acquisition will advance Artis’ strategy of building a differentiated platform to accelerate gene-to-drug discovery across a range of therapeutic modalities by adding fast and cost-effective enzymatic-based synthetic DNA manufacturing cap...